Mini Review

Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers

  • Laboratory Investigation volume 98, pages 4150 (2018)
  • doi:10.1038/labinvest.2017.128
  • Download Citation
Received:
Revised:
Accepted:
Published:

Abstract

Sarcomas are a rare group of tumors of mesenchymal origin. Metastatic sarcomas are often difficult to treat and unresponsive to standard radio- and chemotherapy, resulting in a poor survival rate for patients. Novel treatments with immune checkpoint inhibitors have been proven to prolong survival of patients with a variety of cancers, including metastatic melanoma, lung, and renal cell carcinoma. Since immune checkpoint inhibitors could provide a novel treatment option for patients with sarcomas, clinical trials investigating their efficacy in these group of tumors are ongoing. However, the discrimination of patients that are the most likely to respond to these treatments is still an obstacle in the design of clinical trials. In this review, we provide a brief overview of the mechanisms of action of immune checkpoint inhibitors and discuss the proposed biomarkers of therapy response, such as lymphocytic infiltration, intratumoral PD-L1 expression, and mutational load in sarcomas.

  • Subscribe to Laboratory Investigation for full access:

    $374

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , , et al. The epidemiology of sarcoma. Clin Sarcoma Res 2012;2:14.

  2. 2.

    , , et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011;117:1049–1054.

  3. 3.

    , , et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.

  4. 4.

    , , et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015;33:1191–1196.

  5. 5.

    , , et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311–319.

  6. 6.

    , , et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.

  7. 7.

    , , et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134–144.

  8. 8.

    , , et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–2520.

  9. 9.

    , , et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–2465.

  10. 10.

    , , et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558–562.

  11. 11.

    , . Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 2015;27:39–46.

  12. 12.

    , , . New strategies in sarcoma: linking genomic and immunotherapy approaches to molecular subtype. Clin Cancer Res 2015;21:4753–4759.

  13. 13.

    , , et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275–287.

  14. 14.

    , , et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 2016;6:827–837.

  15. 15.

    . Cancer; a biological approach. I. The processes of control. Br Med J 1957;1:779–786.

  16. 16.

    , , et al. Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol 2006;176:61–67.

  17. 17.

    , . Cell biology of T cell activation and differentiation. Int Rev Cytol 2006;250:217–274.

  18. 18.

    , , . Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Immunol Res 1996;15:38–49.

  19. 19.

    , , et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271–275.

  20. 20.

    , , et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541–547.

  21. 21.

    , , et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985–988.

  22. 22.

    , , et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 2012;35:89–97.

  23. 23.

    , , et al. PD-L1 expression is associated with advanced non-small cell lung cancer. Oncol Lett 2016;12:921–927.

  24. 24.

    , , et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141–151.

  25. 25.

    , , . T-cell exhaustion: characteristics, causes and conversion. Immunology 2010;129:474–481.

  26. 26.

    , , et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007;110:186–192.

  27. 27.

    , , et al. PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. Oncoimmunology 2016;5:e1131379.

  28. 28.

    , , et al. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol 2015;26:1980–1987.

  29. 29.

    , , et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood 2016;127:3026–3034.

  30. 30.

    , . Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med 2015;12:74–78.

  31. 31.

    , , et al. The prognostic value of tumor-associated macrophages in leiomyosarcoma: a single institution study. Am J Clin Oncol 2011;34:82–86.

  32. 32.

    , , et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006;103:690–695.

  33. 33.

    , , et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 2017;9:389.

  34. 34.

    , , et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol 2017.

  35. 35.

    , , et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 2001;61:6868–6875.

  36. 36.

    , , et al. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res 2006;66:1818–1823.

  37. 37.

    , , et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004;4:7.

  38. 38.

    , , et al. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 2015;28:587–595.

  39. 39.

    , , et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): final results of SARC028 and biomarker analyses. J Clin Oncol 2017;35(15_suppl):11008–11008.

  40. 40.

    , , et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res 2016;6:24.

  41. 41.

    , , et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013;2013:168145.

  42. 42.

    , , et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–571.

  43. 43.

    , , et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960–1964.

  44. 44.

    , , et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303–1310.

  45. 45.

    , , et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326–8331.

  46. 46.

    , , et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075–2081.

  47. 47.

    , , et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother 2015;38:96–106.

  48. 48.

    , , et al. Description of the immune microenvironment of chondrosarcoma and contribution to progression. Oncoimmunology 2017;6:e1265716.

  49. 49.

    , , et al. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin Pathol 2012;12:5.

  50. 50.

    , , et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE 2013;8:e82870.

  51. 51.

    , , et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 2011;223:347–357.

  52. 52.

    , , et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 2016;6:30093.

  53. 53.

    , , et al. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol 2016;29:1028–1037.

  54. 54.

    , , et al. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol 2006;30:75–82.

  55. 55.

    , , et al. Inflammatory myofibroblastic tumour of the gallbladder. World J Surg Oncol 2005;3:24.

  56. 56.

    , , et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer 2017;123:3291–3304.

  57. 57.

    , , et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.

  58. 58.

    , , et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS ONE 2013;8:e65821.

  59. 59.

    , , et al. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas. Hum Pathol 2005;36:357–363.

  60. 60.

    , , et al. PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocations. Int J Cancer 2003;104:175–178.

  61. 61.

    , , et al. Mutational analysis of p53 and PTEN in soft tissue sarcoma. Mol Med Rep 2012;5:457–461.

  62. 62.

    , , et al. Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma. Cell Death Differ 2015;22:1785–1791.

  63. 63.

    , , . Classification, molecular characterization, and the significance of pten alteration in leiomyosarcoma. Sarcoma 2012;2012:380896.

  64. 64.

    , , et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 2017;46:197–204.

  65. 65.

    , , et al. Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget 2015;6:12234–12247.

  66. 66.

    , , et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2014;2:690–698.

  67. 67.

    , , et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013;19:3462–3473.

  68. 68.

    , , et al. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol 2016;33:93.

  69. 69.

    , , et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 2016;16:434.

  70. 70.

    , , et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189–2199.

  71. 71.

    , , et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–128.

  72. 72.

    , , et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015;350:207–211.

  73. 73.

    , . Neoantigens in cancer immunotherapy. Science 2015;348:69–74.

  74. 74.

    , , et al. Signatures of mutational processes in human cancer. Nature 2013;500:415–421.

  75. 75.

    , , et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214–218.

  76. 76.

    , , . Unfolding the mutational landscape of human melanoma. J Invest Dermatol 2015;135:659–662.

  77. 77.

    , , et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 2014;7:104–112.

  78. 78.

    , , et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet 2014;10:e1004475.

  79. 79.

    , , et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov 2014;4:1326–1341.

  80. 80.

    , , et al. Exome sequencing of uterine leiomyosarcomas identifies frequent mutations in TP53, ATRX, and MED12. PLoS Genet 2016;12:e1005850.

  81. 81.

    , , et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 2013;45:923–926.

  82. 82.

    , , et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun 2015;6:7557.

  83. 83.

    , , et al. The genomic landscape of epithelioid sarcoma cell lines and tumours. J Pathol 2016;238:63–73.

  84. 84.

    , , et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153–158.

  85. 85.

    , , et al. Genomic landscape of liposarcoma. Oncotarget 2015;6:42429–42444.

  86. 86.

    , . Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. Clin Lab Med 2005;25:179–196.

  87. 87.

    , , et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol 2009;22:1186–1195.

  88. 88.

    , , et al. Microsatellite instability in sarcoma: fact or fiction? ISRN Oncol 2012;2012:473146.

  89. 89.

    , , et al. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 2006;19:1333–1338.

  90. 90.

    , , et al. Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas. Int J Gynecol Pathol 2014;33:483–491.

  91. 91.

    , , et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920–1928.

  92. 92.

    , , et al. Hyper-progressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017;23:4242–4250.

  93. 93.

    , , et al. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453–3459.

  94. 94.

    , , et al. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 2009;62:1127–1135.

  95. 95.

    , , et al. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer 1995;64:342–346.

  96. 96.

    , , et al. CD8(+) tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer 2014;134:2393–2402.

  97. 97.

    , , et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013;73:3499–3510.

  98. 98.

    , , et al. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma 2015;2015:547460.

  99. 99.

    , , et al. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Oncotarget 2016;7:64300–64308.

  100. 100.

    , , et al. CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study. Oncoimmunology 2015;4:e990800.

  101. 101.

    , , et al. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother 2017;66:119–128.

  102. 102.

    , , et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 2015;46:357–365.

  103. 103.

    , , et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 2013;45:131–132.

  104. 104.

    , , et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 2014;46:376–379.

  105. 105.

    , , et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet 2014;46:1170–1172.

Download references

Author information

Affiliations

  1. Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands

    • Robin Veenstra
    • , Marie Kostine
    • , Anne-Marie Cleton-Jansen
    • , Noel FCC de Miranda
    •  & Judith VMG Bovée

Authors

  1. Search for Robin Veenstra in:

  2. Search for Marie Kostine in:

  3. Search for Anne-Marie Cleton-Jansen in:

  4. Search for Noel FCC de Miranda in:

  5. Search for Judith VMG Bovée in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to Judith VMG Bovée.